** Shares of drugmaker Eyenovia EYEN.O rise 6.1% to 11 cents premarket
** EYEN says it will take additional actions to reduce ongoing personnel-related costs by more than 70%
** Co adds investment firm Avenue Capital has agreed to restructure loan agreement and delay EYEN's debt repayments, including principal and interest, until February 2025
** As of Nov. 19, EYEN owed $10.1 million in principal and accrued interest under the agreement with Avenue Capital, according to a regulatory filing earlier this week
** EYEN had 57 full-time employees as of March 15, according to its latest annual report
** Co has been evaluating alternatives after its experimental drug-device combination for an eye disease failed in a late-stage study earlier this month
** As of last close, stock had fallen ~95% YTD
(Reporting by Kamal Choudhury in Bangalore)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。